Chief Executive – Eric Low
Eric has been at Myeloma UK since its inception. He is instrumental in developing the organisation’s unique and innovative strategy which is systematically addressing and removing the barriers that are preventing or slowing down research, and the development and access to new treatments, optimal care and information and support.
Eric has sat and currently sits on a number of national and international myeloma and cancer-related boards, committees and steering groups. These include the National Cancer Research Institute (board member), Myeloma Patients Europe (founding president and current board member), Myeloma Canada (board member), the UK Myeloma Forum (executive committee member), Amyloidosis Research Consortium (board member) and the Ethical Medicines Industry Group. He also sits on the expert advisory group as part of the Accelerated Access Review.
Eric said, “The main goal for Myeloma UK is to improve patient outcomes and ultimately, find a cure for myeloma. We are the driving force behind improving standards of treatment and care for patients and their families and work with multiple stakeholders to ensure that patient-centred research and development is a top priority.”
Follow Eric on Twitter @EricLowMUK